India, May 19 -- Talphera Inc. (TLPH), a specialty pharmaceutical company, on Thursday announced its first quarter financial results, and provided various operational updates.
The company's lead product Niyad is a lyophilized form of nafamostat, a potential anticoagulant, anti-inflammatory and anti-viral agent, and was granted a breakthrough device designation by the FDA.
Q1 2026:
Talphera recorded a net loss of $2.56 million, or $0.04 per share in the first quarter, while in the same period of 2025 it reported a net loss of $2.59 million, or $0.10 per share.
Research and development (R&D) and General and administrative (G&A) expenses combined amounted to $3.95 million, increased from the $2.92 million reported in the previous year. The...